Dassault Systèmes Completes Acquisitive of ArisGlobal, Advances Plan for Integrated Life Sciences AI Platform
IT DAILY ·
✦ AI Summary
Dassault Systèmes said it has completed its acquisition of ArisGlobal and is pursuing the buildout of an integrated AI platform that combines its life sciences and healthcare capabilities.
The platform aims to connect science, medicine, and patients, while accelerating drug discovery and improving therapies and decision-making.
The ArisGlobal platform provides a single source of truth for regulatory, safety, quality, and medical work, and is used by more than 200 customers, including half of the global top 50 biopharma companies.
BizCrushWant to follow Korean talks and live streams in real time?Try CapCrush on the web
Dassault Systèmes said it has completed its acquisition of ArisGlobal and, on the 17th, announced plans to pursue the buildout of an integrated AI platform based on combining its life sciences and healthcare capabilities. The goal of the integrated AI platform is to connect science, medicine, and patients.
Through this, Dassault Systèmes plans to accelerate drug discovery and improve therapies and decision-making. The terms of the acquisition include a cash payment of USD 1.8 billion at closing, with the potential for an additional payment of up to USD 200 million depending on whether AI-related revenue targets are met over the next several years.
ArisGlobal's platform is an AI-native platform that provides a single source of truth for regulatory, safety, quality, and medical work. According to the company, the platform is used by more than 200 customers, including half of the global top 50 biopharma companies.
Dassault Systèmes said it will expand its business scope through this acquisition. Based on the deal, the company plans to build an AI-native integrated platform that connects scientific discovery, clinical development, manufacturing, and real-world patient care outcomes. Dassault Systèmes presented a vision of combining AI, science, virtual twins, and expertise in 3DUniverses, and of turning data into actionable insights by providing context for AI.
Dassault Systèmes has created the position of Executive Vice President and CEO for Life Sciences and Healthcare and appointed Dr. Ashwini Zenooz. Dr. Ashwini Zenooz will oversee Medidata, BIOVIA, and ArisGlobal, and will be responsible for strategy, integration, go-to-market, and sales.
Dassault Systèmes said it has accumulated expertise in life sciences and healthcare over the past 10 years. BIOVIA has handled modeling and simulation in the sciences, while Medidata has taken on clinical development. Dassault Systèmes has also continued to introduce virtual twins into manufacturing and operations.
In 2020, Dassault Systèmes presented a vision to expand the scope of virtual twins. The direction of that expansion was to move from objects to life.
Pascal Daloz, CEO and Chairman of Dassault Systèmes, explained a vision to integrate Dassault Systèmes' life sciences portfolio within 3DUniverses and connect the entire pharmaceutical lifecycle into a single AI-native enterprise platform. He said this would enable a continuous cycle of discovery, learning, and improvement, make each stage interconnected and informative, and increase the value of every preceding stage.
Pascal Daloz said this kind of connection refines scientific models, strengthens the information base for clinical trials, and increases manufacturing agility in response to change. He added that it would also contribute to future innovations that improve patient outcomes.
Source: IT DAILY · Yang Seung-gap
Original: https://www.itdaily.kr/news/articleView.html?idxno=242996
References
This article was produced with the help of an automated content generation algorithm.
Source: IT DAILY
View originalThis article was summarized and organized by BizCrush based on the original article from IT DAILY. For exact quotations and full details, please refer to the original article.
